**Question:** Triflusal is a:

A. Nonsteroidal anti-inflammatory drug (NSAID)
B. Angiotensin-converting enzyme (ACE) inhibitor
C. Calcium channel blocker
D. Antioxidant

**Core Concept:** Triflusal is an active substance derived from the hydrolysis of the natural compound, garlic (Allium sativum), which is known for its antiplatelet aggregation properties. Platelet aggregation is a crucial process in the formation of blood clots. Inhibition of platelet aggregation is a therapeutic strategy in several medical conditions, including stroke, acute myocardial infarction, and peripheral artery disease.

**Why the Correct Answer is Right:** Triflusal is a drug that primarily acts as an antiplatelet agent. It achieves this effect by inhibiting the production of thromboxane A2, a potent platelet aggregator, through the inhibition of the enzyme, cyclooxygenase (COX-1). This leads to a decreased risk of thrombosis and subsequent vascular events.

**Why Each Wrong Option is Incorrect:**

A. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of drugs that primarily target inflammation by inhibiting cyclooxygenase (COX) enzymes. Triflusal, however, is a specific inhibitor of COX-1, not a broad NSAID.

B. Angiotensin-converting enzyme (ACE) inhibitors are medications used in the management of hypertension and heart failure, primarily through blockade of the renin-angiotensin system. Triflusal does not target this system, making it unrelated to ACE inhibitors.

C. Calcium channel blockers are drugs that modulate calcium channels, mainly used in the treatment of hypertension, angina pectoris, and arrhythmias. Triflusal does not target calcium channels or regulate vascular smooth muscle contraction, making it unrelated to calcium channel blockers.

D. Antioxidants are substances that neutralize free radicals and protect cells from oxidative damage. Triflusal, as an antiplatelet agent, does not have antioxidant properties; its primary function is unrelated to oxidation.

**Clinical Pearl:** Triflusal exhibits its antiplatelet effect through selective inhibition of COX-1 enzymes, which prevents the formation of thromboxane A2, a potent platelet aggregator. By reducing platelet aggregation, triflusal helps prevent thrombotic events like stroke, myocardial infarction, and peripheral vascular disease. In contrast, the wrong options target different physiological processes and mechanisms, making them irrelevant to triflusal's primary action as an antiplatelet agent.